| |
Volume (mm3)
|
Tg (ng/ml)
|
VRR (%)
|
---|
Patient no.
|
Nodule no.
|
Initial
|
24 months later
|
Initial
|
24 months later
|
24 months later
|
---|
1
|
1F
|
11,448
|
86
|
>300
|
147.0
|
99
|
2
|
2
|
259
|
0
|
6.2
|
4.9
|
100
|
3
|
919
|
0
|
6.2
|
4.9
|
100
|
4
|
1507
|
75
|
6.2
|
4.9
|
95
|
3
|
5
|
528
|
60
|
7.9
|
2.9
|
89
|
6
|
528
|
46
|
7.9
|
2.9
|
93
|
4
|
7
|
308
|
0
|
35.2
|
13.2
|
100
|
5
|
8
|
251
|
25
|
72.4
|
6.9
|
90
|
9
|
55
|
0
|
72.4
|
6.9
|
100
|
10
|
31
|
0
|
72.4
|
6.9
|
100
|
11
|
141
|
0
|
72.4
|
6.9
|
100
|
6
|
12
|
299
|
31
|
57.0
|
1.1
|
90
|
13
|
147
|
21
|
57.0
|
1.1
|
86
|
14
|
88
|
0
|
57.0
|
1.1
|
100
|
7
|
15
|
4875
|
293
|
114.8
|
0.7
|
94
|
16
|
1879
|
264
|
114.8
|
0.7
|
85
|
17
|
2327
|
205
|
114.8
|
0.7
|
91
|
18
|
94
|
0
|
114.8
|
0.7
|
100
|
8
|
19
|
4767
|
121
|
1.0
|
< 0.2
|
97
|
9
|
20
|
11
|
0
|
17.5
|
< 0.2
|
100
|
21
|
15
|
0
|
17.5
|
< 0.2
|
100
|
10
|
22G
|
2010
|
1099
|
8.6
|
< 0.2
|
45
|
23
|
513
|
377
|
8.6
|
< 0.2
|
26
|
11
|
24
|
13
|
0
|
< 0.2
|
< 0.2
|
100
|
12
|
25
|
1717
|
502
|
51
|
20.1
|
71
|
13
|
26H
|
19,225
|
301
|
119.0
|
60.4
|
98
|
27
|
2010
|
63
|
119.0
|
60.4
|
97
|
28
|
612
|
91
|
119.0
|
60.4
|
86
|
29
|
518
|
21
|
119.0
|
60.4
|
96
|
14
|
30
|
1281
|
403
|
21.6
|
6.5
|
69
|
15
|
31
|
25,017
|
2213
|
>300
|
90.5
|
91
|
16
|
32
|
314
|
0
|
18.2
|
3.2
|
100
|
17
|
33
|
452
|
27
|
0.8
|
0.3
|
94
|
18
|
34
|
5256
|
1495
|
>300
|
>300
|
72
|
35
|
3843
|
1143
|
>300
|
>300
|
70
|
36I
|
151
|
94
|
>300
|
>300
|
38
|
- F During the 9th month of follow-up, CEUS indicated partial re-hyper-enhancement of No. 1 nodule, so the secondary implantation was performed
- G US-guided puncture biopsy of No.22 nodule during follow-up indicated that there was no definite metastatic cancer was found
- H During the third month of follow-up, VRR and the serum Tg level reduction of No. 26 nodule were both less than 50%, so the secondary implantation was performed
- I Although VRR reduction of No. 36 nodules were less than 50%, and the serum Tg value > 300 ng/ml, CEUS indicated low to no enhancement of the nodule